Clinical Trials
Gilead Terminates Phase III Clinical Trial of Ambrisentan in Patients with Idiopathic Pulmonary Fibrosis
Gilead Sciences, Inc.announced it is stopping ARTEMIS-IPF, the company's ongoing Phase III clinical trial of ambrisentan in patients with idiopathic pulmonary fibrosis (IPF), due to lack of efficacy. This decision follows an interim analysis...
Clinical Trials
Genentech Phase II study shows Pertuzumab and Herceptin Plus Chemotherapy Significantly Improved the Rate of Complete Tumor
Genentech, a member of the Roche Group announced results from the NEOSPHERE trial, a Phase II neoadjuvant study evaluating the effect of a novel combination regimen of pertuzumab and Herceptin® (trastuzumab) plus chemotherapy (docetaxel) in women with early-stage, HER2-positive...
Clinical Trials
Novartis study shows drug Afinitor plus hormonal therapy delays disease progression in advanced metastatic breast cancer patients
A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor...
Clinical Trials
Phase III study showed Rituxan/MabThera decreased the risk of needing later treatment with chemotherapy or radiotherapy by 80% by Roche
Roche announced positive data from a Phase III study of Rituxan/MabThera (rituximab) in patients with advanced follicular lymphoma who did not have symptoms of disease (asymptomatic disease). Based on results of previous studies1 that showed no...
Clinical Trials
QR Pharma receives FDA clearance to conduct clinical trials with its second novel Alzheimer compound
 QR Pharma, Inc., a developer of novel drugs to treat Alzheimer's disease (AD), announced today that the United States Food and Drug Administration (FDA) has accepted the Investigational New Drug application (IND) to begin human clinical trials and...
Clinical Trials
Bayer and Regeneron Report Positive Top-Line Results of Two Phase 3 Studies
Bayer HealthCare and Regeneron Pharmaceuticals, Inc. announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every...
Clinical Trials
Reata and Abbott Announce Positive Phase 2b Study Results for Bardoxolone Methyl
Abbott Park, Illinois-Reata Pharmaceuticals and Abbott today announced data from a Phase 2b study which suggests that bardoxolone methyl, an investigational treatment for chronic kidney disease (CKD), may reduce the stage of CKD and improve estimated glomerular filtration rate...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read